Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized controlled trial of erlotinib (Tarceva) as maintenance therapy in resected head and neck squamous cell carcinoma
2006-001845-33Phase 3Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of erlotinib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Roche Farma, S.A. Primary endpoints: Progression-free survival time at 2 years and Proportion of patients progression-free at 2 years. Started Mar 2010; status: completed.
02
Drugs
erlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-001845-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001845-33.